Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chongqing Lummy Pharma In-licenses China Rights to Cancer Immunotherapy

publication date: Apr 14, 2015

Chongqing Lummy Pharma in-licensed greater China rights to Arcelis®, a cancer immunotherapy platform developed by Argos Therapeutics of North Carolina. Yesterday, Lummy announced it had invested in a $50 million China Fund with TVM Capital for in-licensing, and today the company followed up with a deal that will consume a large part of the funds. The agreement calls for an upfront purchase of $10 million worth of Argos stock by Lummy and the TVM-sponsored China BioPharma Capital I Fund and provides for an additional $30 million in milestone payments. More details.....

Stock Symbols: (SHZ: 300006) (NSDQ: ARGS)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital